

IBD Registry

Biological Therapies Audit

Statement of Purpose, Scope and Requirements



Background

The IBD Registry Biologics Audit is a continuation of the National IBD Biological Therapies Audit previously funded by NHS England and managed by the Royal College of Physicians. As of January 2017 this Audit has become part of the IBD Registry Programme.

NHS England and the Welsh Government have decommissioned IBD as part of the NCAPOP however participation in the IBD Biologics Audit remains part of the Quality Accounts reporting requirements for Trusts in 2018/19 and 2019/2020. In the absence of NHS England funding, the IBD Registry makes a small annual subscription from participating Trusts to cover the costs of the KPI analytics and supporting Registry.

Quality Improvement Aims

Patient perspective – All patients with IBD receiving biological therapy should be adequately screened before initiation and the safety and effectiveness of the therapy reviewed post-induction and each year.

Patients should be asked to consent to their data being submitted to the Registry.

Clinical Team perspective – The IBD Clinical Team should have a safe, efficient and secure electronic system for recording and accessing the key demographic and clinical data on all patients receiving biological therapy. The team should be resourced to ensure the minimum data is routinely entered. Management and Governance perspective - Trust management and Commissioners should be able to review key demographic and clinical data on the use of biological therapies on a regular basis to assure quality and value for money. They should have access to national benchmarking on key indicators at least annually.

Scope of data collection

Data collection has been reduced to the minimum necessary to report the key clinical indicators which are compliance with ECCO guidance on pre-treatment screening and compliance with NICE recommendations for follow-up review of patients receiving biological therapies. Data collection is prospective and continuous with quarterly uploads of data to the Registry via NHS Digital. The data includes a minimum of patient identifiable demographics to enable linkage by NHS Digital of the Audit data to routine Hospital Episode Statistics (HES) data when this is published.

Related documents:

(1) Rationale and description of the IBD Registry Biologics Audit KPIs (2019-20)

Audit reporting

Participating Trusts will receive feedback reports on their performance against the KPIs following each quarterly submission, along with their full Registry report reflecting local and National data submissions. A summarised of this data will be made available each year as part of our annual report.

Participation requirements

Technical - IBD teams will need access to an electronic system that captures the key demographic and clinical data. This system will need to be capable of exporting the relevant data in the format required by NHS Digital. (cf. The IBD Registry Data Submission Framework) Trusts may develop their own EPR system to capture and export the data and the Registry has set out the technical requirements in the IBD Registry Data Specification Framework. Alternatively, Trusts can purchase one of the commercially-available IBD Patient Management Systems that is IBD Registry-compliant. For Trusts without a suitable Electronic Patient Record (EPR), the IBD Registry provides a Web Tool. This tool not only captures and exports the Biologics Audit data, but also provides a clinical management system for IBD care. See our website for further information.

Information Governance – As some patient-identifiable demographic data is included in the Audit dataset, NHS Digital require the Trust's Caldicott Guardian to confirm the Trust has authorised submission of this data before access is granted to their Clinical Audit Platform. The IBD Registry is looking to consent all patients for Registry participation moving forwards. Progress towards this objective is one of the Audit KPIs.

Data entry resource – it is important that adequate resource is provided to the IBD team to undertake the routine entry of the required audit data.

Annual Trust Quality Accounts subscription is £2000 (+ VAT) p.a. In order to maintain the IBD Registry Biologics Audit, including all its KPI analytics, the Registry makes a cost recovery charge.

Further information

Additional information about the IBD Registry is available at www.ibdregistry.org.uk and on the Biological Therapies Audit and Quality Accounts at www.ibdregistry.org.uk/qualityaccounts
For any queries, please email the IBD Registry at support@ibdregistry.org.uk